Optimizing treatment in recurrent epithelial ovarian cancer.

Item

http://www.wikidata.org/entity/Q47549019

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Optimizing treatment in recurrent epithelial ovarian cancer.

@en

Optimizing treatment in recurrent epithelial ovarian cancer.

@nl

type

Item

label

Optimizing treatment in recurrent epithelial ovarian cancer.

@en

Optimizing treatment in recurrent epithelial ovarian cancer.

@nl

prefLabel

Optimizing treatment in recurrent epithelial ovarian cancer.

@en

Optimizing treatment in recurrent epithelial ovarian cancer.

@nl

P1476

Optimizing treatment in recurrent epithelial ovarian cancer.

@en

P2093

Eleonora Palluzzi

http://www.w3.org/2001/XMLSchema#string

Gabriella Ferrandina

http://www.w3.org/2001/XMLSchema#string

Giacomo Corrado

http://www.w3.org/2001/XMLSchema#string

Giovanni Scambia

http://www.w3.org/2001/XMLSchema#string

Maria Grazia Distefano

http://www.w3.org/2001/XMLSchema#string

Vanda Salutari

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

Cancer statistics, 2016

Optimal chemotherapy treatment for women with recurrent ovarian cancer

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovaria

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.

The biology of ovarian cancer: new opportunities for translation

WEE1 tyrosine kinase, a novel epigenetic modifier

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

P304

1147-1158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737140.2017.1398088

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29086618

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer